Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ann Michelini"'
Autor:
David P. Ryan, Jeffrey G. Supko, Robert J. Mayer, Clinton F. Stewart, Janet Dancey, Kate Kinsella, Jeffrey A. Meyerhardt, Craig C. Earle, Peter C. Enzinger, Charles S. Fuchs, Jeffrey W. Clark, Shuji Ogino, Ann Michelini, Joseph Paul Eder, Andrew X. Zhu, Ferdinando D’Amato
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:661-670
To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in patients with previously untreated advanced colorectal cancer.Startin
Autor:
Susan Sheehan, Ann Michelini, David P. Ryan, Jeffrey A. Meyerhardt, Charles S. Fuchs, Peter C. Enzinger, Andrew X. Zhu, Craig C. Earle, Jeffrey W. Clark, Matthew H. Kulke, Michele Vincitore
Publikováno v:
Journal of Clinical Oncology. 24:1892-1897
Purpose To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer. Patients and Methods Patients were eligible if they had metastatic colorectal cancer that pro
Autor:
David P. Ryan, Jeffrey W. Clark, Keith Stuart, Charles S. Fuchs, Michele Vincitore, Matthew H. Kulke, Peter C. Enzinger, Alona Muzikansky, Ann Michelini
Publikováno v:
Journal of Clinical Oncology. 24:401-406
Purpose Standard, intravenous chemotherapy regimens for neuroendocrine tumors have been associated with limited response rates and significant toxicity. We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with met
Autor:
Kate Kinsella, Shuji Ogino, Jeffrey A. Meyerhardt, Peter C. Enzinger, Takako Kawasaki, Chungdak Namgyal, Ann Michelini, Matthew H. Kulke, Mohan Brahmandam, Jeffrey W. Clark, David P. Ryan, Mami Cantor, Massimo Loda, Charles S. Fuchs
Publikováno v:
Clinical Cancer Research. 11:6650-6656
Purpose: Recently, activating mutations of the epidermal growth factor receptor (EGFR) gene were discovered in non–small cell lung cancers sensitive to gefitinib (ZD1839, an EGFR tyrosine kinase inhibitor) but not in gefitinib-resistant cancers. Ab
Autor:
Peter C. Enzinger, Jeffrey W. Clark, Haesook T. Kim, Jeffrey A. Morgan, Matthew H. Kulke, Thomas J. Lynch, Ann Michelini, Michele Vincitore, Charles S. Fuchs
Publikováno v:
Cancer. 101:934-939
BACKGROUND Treatment with traditional cytotoxic chemotherapy regimens containing streptozocin or dacarbazine has resulted in only marginal benefit for patients with metastatic neuroendocrine tumors. The use of these regimens has been further limited
Autor:
Ann Michelini, Tanya P. Sengupta, Lindsey R. Baden, Matthew H. Kulke, Abraham B. Schwarzberg, Elizabeth H. Stover, Michele Vincitore
Publikováno v:
Cancer investigation. 25(4)
Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia. We evaluated the incidence of lymphopenia and opportunistic infections during treatment and up to 12 months f
Autor:
Matthew H. Kulke, William E. Fogler, Peter C. Enzinger, John V. Heymach, Charles S. Fuchs, Emily K. Bergsland, David P. Ryan, Kate Kinsella, Jeffrey A. Meyerhardt, C. Sidor, Andrew X. Zhu, Alan P. Venook, Thomas J. Lynch, Ann Michelini
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(22)
Purpose Endostatin is a 20-kd proteolytic fragment of collagen XVIII that, in preclinical studies, has been shown to have antiangiogenic and antitumor activity. Both preclinical and human phase I studies of recombinant human endostatin (rhEndostatin)
Autor:
Matthew H. Kulke, Peter C. Enzinger, Jeffrey W. Clark, Michele Vincitore, Charles S. Fuchs, Thomas J. Lynch, Bingyan Wu, Ann Michelini
Publikováno v:
Cancer investigation. 24(3)
The combination of epirubicin, cisplatin, and infusional 5-fluorouracil (ECF) currently represents a standard and effective regimen for the treatment of advanced gastroesophageal cancer. The use of doxorubicin as an alternative to epirubicin in the E
Autor:
Ann Michelini, Matthew H. Kulke, Jeffrey W. Clark, Charles S. Fuchs, Panos Fidias, Alona Muzikansky, Peter C. Enzinger, Kate Kinsella
Publikováno v:
Cancer investigation. 24(4)
Platinum-based combination chemotherapy regimens increasingly are accepted as a first-line treatment option for patients with advanced gastroesophageal adenocarcinoma. While active, such regimens also have been associated with toxicity. Vinorelbine i
Autor:
Matthew H. Kulke, Craig C. Earle, Peter C. Enzinger, Charles S. Fuchs, David P. Ryan, Ann Michelini, A. David McCollum, Bingyan Wu, Jeffrey W. Clark
Publikováno v:
American journal of clinical oncology. 29(1)
With the increasing survival of patients with metastatic colorectal cancer (CRC) there is a growing need for effective second- and third-line agents. We conducted a multicenter, phase II study to examine the combination of capecitabine and thalidomid